San Diego, March 19, 2015 (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces that it has been issued a notice of allowance by the U.S. Patent Office for claims related to a gene classifier for pigmented skin lesion assessment. The gene classifier has been shown to be associated with melanoma skin cancer and can be used by clinicians to evaluate pigmented skin lesions. When used with the Adhesive Skin Sample Collection Kit, it provides a non-invasive measurement of melanoma related gene expression thereby facilitating accurate clinical diagnosis and helping avoid unnecessary surgical biopsies.
John Dobak, M.D., the CEO of DermTech commented, “We currently have the strongest and broadest patent portfolio in the world for non-invasive gene expression testing for skin cancer and other skin conditions. The addition this intellectual property further strengthens and extends the life of our patent portfolio. “
DermTech’s patent portfolio may be found on the company’s website at www.dermtech.com/patents/. The Pigmented Lesion Assay has been tested and validated in multiple clinical studies involving more than 600 samples and over 200 melanomas.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected benefits of DermTech’s technology. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, and launching new products. These forward-looking statements speak only as of the date hereof and DermTech disclaims any obligation to update these statements.
About DermTech
DermTech is a commercial stage dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. For additional information visit: www.dermtech.com.
Media Contact:
Steve Kemper, CPA, MBA, MS
Chief Financial Officer
(858) 450-4222
skemper@dermtech.com